Compare GSAT & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSAT | HALO |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.8B |
| IPO Year | 2006 | N/A |
| Metric | GSAT | HALO |
|---|---|---|
| Price | $53.97 | $78.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $52.75 | ★ $76.42 |
| AVG Volume (30 Days) | 693.6K | ★ 1.8M |
| Earning Date | 02-26-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.68 |
| EPS | N/A | ★ 4.74 |
| Revenue | $262,202,000.00 | ★ $1,242,852,000.00 |
| Revenue This Year | $10.93 | $34.54 |
| Revenue Next Year | $10.72 | $26.28 |
| P/E Ratio | ★ N/A | $16.45 |
| Revenue Growth | 8.54 | ★ 31.19 |
| 52 Week Low | $17.24 | $47.50 |
| 52 Week High | $74.88 | $79.50 |
| Indicator | GSAT | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 37.79 | 69.66 |
| Support Level | $60.21 | $71.23 |
| Resistance Level | $63.00 | $74.48 |
| Average True Range (ATR) | 4.68 | 2.31 |
| MACD | -0.85 | 0.63 |
| Stochastic Oscillator | 0.47 | 91.84 |
Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services. Mobile satellite services are typically used by customers where existing terrestrial wireline and wireless communications networks are impaired or do not exist. The company provides communications services such as two-way voice and data transmission. In addition, one-way data transmission is also offered. Both services are offered using mobile or fixed devices. The company is an owner of satellite assets. It has one reportable segment: MSS business. The company generates the vast majority of its revenue within the United States.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.